[en] UNLABELLED: Infections with respiratory syncytial virus (RSV) can cause severe disease. In young children, RSV is the most common cause of lower respiratory tract illness and life-threatening infections most commonly occur in the first years of life. In adults, elderly and immunocompromised people are most vulnerable. Recently there has been an acceleration in the development of candidate RSV vaccines, monoclonal antibodies and therapeutics which are expected to become available in Europe within the next 2-10 years. Understanding the true burden of childhood RSV disease will become very important to support public health authorities and policy makers in the assessment of new therapeutic opportunities against RSV disease. A systematic literature search was performed to map local data on the burden of RSV disease and to evaluate available RSV surveillance systems. A group of 9 paediatric infectious diseases specialists participated in an expert panel. The purpose of this meeting was to evaluate and map the burden associated with RSV infection in children, including patient pathways and the epidemiological patterns of virus circulation in Belgium. Sources of information on the burden of RSV disease in Belgium are very limited. For the outpatient setting, it is estimated that 5-10% of young patients seen in primary care are referred to the hospital. Around 3500 children between 0 and 12 months of age are hospitalized for RSV-bronchiolitis every year and represent the majority of all hospitalizations. The current Belgian RSV surveillance system was evaluated and found to be insufficient. Knowledge gaps are highlighted and future perspectives and priorities offered.
CONCLUSION: The Belgian population-based RSV surveillance should be improved, and a hospital-led reporting system should be put in place to enable the evaluation of the true burden of RSV disease in Belgium and to improve disease management in the future.
WHAT IS KNOWN: • RSV bronchiolitis is a very important cause of infant hospitalization. • The burden of disease in the community is poorly studied and underestimated.
WHAT IS NEW: • This expert opinion summarizes knowledge gaps and offers insights that allow improvement of local surveillance systems in order to establish a future-proof RSV surveillance system.
Disciplines :
Pediatrics Immunology & infectious disease
Author, co-author :
Raes, Marc; Department of Paediatrics, Jessa Hospital, Hasselt, Belgium. marc.raes@jessazh.be
Daelemans, Siel; Paediatric Pulmonary and Infectious Diseases, University Hospital Brussel, Brussels, Belgium
Cornette, Luc; Department of Neonatology, AZ Sint-Jan Hospital, Brugge, Belgium
Moniotte, Stéphane; Department of Paediatric Cardiology, University Hospital Saint-Luc, UCLouvain, Brussels, Belgium
Proesmans, Marijke; Paediatric Department, University Hospital Gasthuisberg, Leuven, Belgium
Schaballie, Heidi; Department of Paediatric Pulmonology, Infectious Diseases and Immune Disorders, University Hospital, Ghent, Belgium
Frère, Julie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie
Vanden Driessche, Koen; Department of Paediatric Infectious Diseases, University Hospital, Antwerp, Belgium
Van Brusselen, Daan; Department of Paediatric Infectious Diseases, GZA Hospitals, Antwerp, Belgium
Language :
English
Title :
The burden and surveillance of RSV disease in young children in Belgium-expert opinion.
Publication date :
January 2023
Journal title :
European Journal of Pediatrics
ISSN :
0340-6199
eISSN :
1432-1076
Publisher :
Springer Science and Business Media Deutschland GmbH, Germany
Centre for disease Control (2020) RSV in infants and young children. Retrieved from Respiratory Syncytial Virus Infection (RSV): https://www.cdc.gov/rsv/high-risk/infants-young-children.html Accessed 20 Apr 2022
Collins PL, Graham BS (2008) Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82(5):2040–2055. 10.1128/jvi.01625-07 DOI: 10.1128/jvi.01625-07
Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, Dubovsky F, Griffin MP (2018) Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J 37(6):886. 10.1097/inf.0000000000001916 DOI: 10.1097/inf.0000000000001916
Xing Y, Proesmans M (2019) New therapies for acute RSV infections: where are we? 178:131–138. 10.1007/s00431-018-03310-7
Carvajal JJ, Avellaneda AM, Salazar-Ardiles C, Maya JE, Kalergis AM, Lay MK (2019) Host components contributing to respiratory syncytial virus pathogenesis. Front Immunol. 10.3389/fimmu.2019.02152 DOI: 10.3389/fimmu.2019.02152
von Hammerstein AL, Aebi C, Barbey F, Berger C, Buettcher M, Casaulta C, Egli A, Gebauer M, Guerra B, Kahlert C, Kellner E, Kottanattu L, Opota O, Mann C, Meyer Sauter P, Plebani M, Ritz N, Testi C, von Niederhäusern V, Wagner N, Zimmermann P, Zucol F, Agyeman PKA, Trück J (2021) Interseasonal RSV infections in Switzerland-rapid establishment of a clinician-led national reporting system (RSV EpiCH). Swiss Med Wkly 151:w30057. 10.4414/smw.2021.w30057 DOI: 10.4414/smw.2021.w30057
Openshaw PJ, Chiu C, Culley FJ, Johansson C (2017) Protective and harmful immunity to RSV infection. Annu Rev Immunol 35:501–532. 10.1146/annurev-immunol-051116-052206 DOI: 10.1146/annurev-immunol-051116-052206
Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Jill CJ, Madhi SA, Omer SB, Simoes EAF, Campbell H, Pariente AB et al (2022) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. The Lancet 399(10340):2047–2064. 10.1016/s0140-6736(22)00478-0 DOI: 10.1016/s0140-6736(22)00478-0
Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJM, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases (2011) Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 17(Suppl 6):E1–E59. 10.1111/j.1469-0691.2011.03672.x DOI: 10.1111/j.1469-0691.2011.03672.x
Cattoir L, Vankeerberghen A, Boel A, Van Vaerenbergh K, De Beenhouwer H (2019) Epidemiology of RSV and hMPV in Belgium: a 10 year follow-up. Acta Clin Belg Int J Clin Lab Med 74:4(229–235). https://doi.org/10.1080/17843286.2018.1492509
Subissi L, Bossuyt N, Reynders M, Gérard M, Dauby N, Bourgeois M, Delaere B, Quoilin S, Van Gucht S, Thomas I, Barbezange C (2020) Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19. Eurosurveillance 25(39):1900627. 10.2807/1560-7917.es.2020.25.39.1900627 DOI: 10.2807/1560-7917.es.2020.25.39.1900627
Van Brusselen D, De Troeyer K, Ter Haar E, Vander Auwera A, Poschet K, Van Nuijs S, Bael A, Stobbelaar K, verhulst S, Van Herendael B, Willems P, Vermeulen M, De Man J, Bossuyt N, Vanden Driesssche K (2021) Bronchiolitis in COVID-19 times: a nearly absent disease? Eur J Pediatr 180(6):1969–1973. 10.1007/s00431-021-03968-6 DOI: 10.1007/s00431-021-03968-6
Voets S, Van Berlaer G, Hachimi-Idrissi S (2006) Clinical predictors of the severity of bronchiolitis. Eur J Emerg Med 13:3(134–138). 10.1097/01.mej.0000206194.85072.33
Greenland JR, Jones KD, Singer JP (2022) Bronchiolitis. In Broaddus V, and Courtney MD, Murray & Nadal’s textbook of respiratory medicine 994–1004 e4. Elsevier. Retrieved from https://www.clinicalkey.com/#!/browse/book/3-s2.0-C20181002991. Accessed 20 Apr 2022
Raes M, Cox B, Strens D, Nawrot TS (2016) Seasonality of respiratory syncytial virus (RSV) in Belgium. Am J Perinatol 33:A024 DOI: 10.1055/s-0036-1592395
Li Y, Johnson EK, Shi T, Campbell H, Chaves SS, Commaille-Chapus C, Dighero I, James SL, Mahé C, Ooi Y, Paget J, van Pomeren T, Viboud C, Nair H (2021) National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study. Lancet Respir Med 9:175–185. 10.1016/S2213-2600(20)30322-2 DOI: 10.1016/S2213-2600(20)30322-2
Yitshak-Sade M, Yudovitch D, Novack V, Tal A, Kloog I, Goldbart A (2017) Air pollution and hospitalization for bronchiolitis among young children. Ann Am Thorac Soc 14(12):1796–1802. 10.1513/annalsats.201703-191oc DOI: 10.1513/annalsats.201703-191oc
Khomenko S, Cirach M, Pereira-Barboza E, Mueller N, Barrera-Gómez J, Rojas-Rueda D et al (2021) Premature mortality due to air pollution in European cities: a health impact assessment. The Lancet Planetary health 5(3):e121–e134. 10.1016/s2542-5196(20)30272-2 DOI: 10.1016/s2542-5196(20)30272-2
Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA, Szilagyi PG, Griffin MR, Williams JV, Zhu Y, Grijalva CG, Prill MM, Iwane MK (2013) Respiratory syncytial virus–associated hospitalizations among children less than 24 months of age. Pediatrics 132(2):e341–e348. 10.1542/peds.2013-0303 DOI: 10.1542/peds.2013-0303
Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM, Lynfield R, Bye E, Como-Sabetti K, Reingold A, Chai S, Daily P, Thomas A, Crawford C, Reed C, Garg S, Chaves SS (2020) Estimated burden of community-onset respiratory syncytial virus–associated hospitalizations among children aged <2 years in the United States, 2014–15. Journal of the Pediatric Infectious Diseases Society 9(5):587–595. 10.1093/jpids/piz087 DOI: 10.1093/jpids/piz087
Rha B, Curns AT, Lively JY, Campbell AP, Englund JA, Boom JA, Azimi PH, Weinberg GA, Staat MA, Selvarangan R, Halasa NB, McNeal MM, Klein EJ, Harrison CJ, Williams JV, Szilagyi PG, Singer MN, Sahni LC, Figueroa-Downing D, McDaniel D, Prill MM, Whitaker BL, Stewart LS, Schuster JE, Pahud BA, Weddle G, Avadhanula V, Munoz FM, Piedra PA, Payne DC, Langley G, Gerber SI (2020) Respiratory syncytial virus–associated hospitalizations among young children: 2015–2016. Pediatrics 146(1):e20193611. 10.1542/peds.2019-3611 DOI: 10.1542/peds.2019-3611
Reeves RM, Hardelid P, Gilbert R, Ellis J, Zhao H, Donati M, Pebody R (2016) Epidemiology of laboratory-confirmed respiratory syncytial virus infection in young children in England, 2010–2014: the importance of birth month. Epidemiol Infect 144(10):2049–2056. 10.1017/s0950268816000352 DOI: 10.1017/s0950268816000352
Wang X, Li Y, Vazquez Fernandez L, Teirlinck AC, Lehtonen T, van Wijhe M, Stona L, Bangert M, Reeves RM, Boas H, van Boven M, Heikkinen T, Klint Johannesen C, Baraldi E, Dona D, Tong S, Campbell H, Respiratory Syncytial Virus Consortium in Europe (RESCUE) Investigators (2022) Respiratory syncytial virus–associated hospital admissions and bed days in children <5 years of age in 7 European countries. J Infect Dis. 10.1093/infdis/jiab560 DOI: 10.1093/infdis/jiab560
Cromer D, Van Hoek AJ, Newall AT, Pollard AJ, Jit M (2017) Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. The lancet Public health 2(8):e367–e374. 10.1016/s2468-2667(17)30103-2 DOI: 10.1016/s2468-2667(17)30103-2
Chung A, Reeves RM, Nair H, Campbell H, RESCUE investigators (2020) Hospital admission trends for bronchiolitis in Scotland, 2001–2016: a national retrospective observational study. J Infect Dis Suppl 7:S592–S598. 10.1093/infdis/jiaa323 DOI: 10.1093/infdis/jiaa323
De Jaeger A, Biarent D, Clement de Clety S (2018) BE-PICU-register. Belgium: Federal Public Service Health, Food Chain Safety and Environment. Retrieved from https://overlegorganen.gezondheid.belgie.be/sites/default/files/documents/picu-2020-02-report.pdf Accessed 20 Apr 2022
Lively JY, Curns AT, Weinberg GA, Edwards KM, Staat MA, Prill MM, Gerber SI, Langley GE (2019) Respiratory syncytial virus–associated outpatient visits among children younger than 24 months. Journal of the Pediatric Infectious Diseases Society 8(3):284–286. 10.1093/jpids/piz011 DOI: 10.1093/jpids/piz011
Gill CJ, Mwananyanda L, MacLeod WB, Kwenda G, Pieciak R, Mupila Z, Murphy C, Chikoti C, Forman L, Berklein F, Lapidot R, Chimoga C, Ngoma B, Larson A, Lungu J, Nakazwe R, Nzara D, Pemba L, Yankonde B, Chirwa A, Mwale M, Thea DM (2022) Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project. Lancet Glob Health 10(2):e269–e277. 10.1016/s2214-109x(21)00518-0 DOI: 10.1016/s2214-109x(21)00518-0
Chaw PS, Wong SW, Cunningham S, Campbell H, Mikolajczyk R, Nair H, Investigators R (2020) Acute lower respiratory infections associated with respiratory syncytial virus in children with underlying congenital heart disease: systematic review and Meta-analysis. J Infect Dis 222(Suppl 7):S613–S619. 10.1093/infdis/jiz150 DOI: 10.1093/infdis/jiz150
Chaw PS, Hua L, Cunningham S, Campbell H, Mikolajczyk R, Nair H, Investigators R (2020) Respiratory syncytial virus-associated acute lower respiratory infections in children with bronchopulmonary dysplasia: systematic review and meta-analysis. J Infect Dis 222(Suppl 7):S620–S627. 10.1093/infdis/jiz492 DOI: 10.1093/infdis/jiz492
Weinberger DO, Klugman KP, Steiner CA, Simonsen L, Vivoud C (2015) Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data. PLoS Med 12(1):e1001776. 10.1371/journal.pmed.1001776 DOI: 10.1371/journal.pmed.1001776
Stensballe LG, Hjuler T, Andersen A, Kaltoft M, Ravn H, Aaby P, Simoes EA (2008) Hospitalization for respiratory syncytial virus infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based cohort study. Clin Infect Dis 46(8):1165–1171. 10.1086/529438 DOI: 10.1086/529438
Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, Bont L, Dutch RSV Neonatal Network (2013) Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 368(19):1791–1799. 10.1056/nejmoa1211917 DOI: 10.1056/nejmoa1211917
Mauskopf J, Margulis AV, Samuel M, Lohr KN (2016) Respiratory syncytial virus hospitalizations in healthy preterm infants: systematic review. Pediatr Infect Dis J 35(7):e299. 10.1097/inf.0000000000001163 DOI: 10.1097/inf.0000000000001163
Shi T, Ooi Y, Zaw EM, Utjesanovic N, Campbell H, Cunningham S, Bont L, Nair H, Investigators RESCEU (2020) Association between respiratory syncytial virus-associated acute lower respiratory infection in early life and recurrent wheeze and asthma in later childhood. J Infect Dis 222(Suppl 7):S628–S633. 10.1093/infdis/jiz311 DOI: 10.1093/infdis/jiz311
Díez-Domingo J, Pérez-Yarza EG, Melero JA, Sánchez-Luna M, Aguilar MD, Blasco AJ, Alfaro N, Lázaro P (2014) Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis 14(1):1–14. 10.1186/s12879-014-0544-x DOI: 10.1186/s12879-014-0544-x
Mitchell I, Defoy I, Grubb E (2017) Burden of respiratory syncytial virus hospitalizations in Canada. Canadian Resp J ID4521302. https://doi.org/10.1155/2017/4521302
Young M, Smitherman L (2021) Socioeconomic impact of RSV hospitalization. Infect Dis Ther Mar 10 (Suppl1):35–45. 10.1007/s40121-020-00390-7
Moreel L, Proesmans M (2020) High flow nasal cannula as respiratory support in treating infant bronchiolitis: a systematic review. Eur J Pediatr 179(5):711–718. 10.1007/s00431-020-03637-0 DOI: 10.1007/s00431-020-03637-0
Synagis reimbursement criteria. Retrieved from https://webappsa.riziv-inami.fgov.be/SSPWebApplicationPublic/nl/Public/RequestForm. Accessed 22 Sept 2022
EPAR (2021) Palivizumab summary of product characteristics. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/synagis#product-information-section. Accessed 20 Apr 2022
Mazur NI, Terstappen J, Baral R, Bardaji A, Beutels P, Buchholz UJ, Cohen C, Crowe JE, Cutland CL, Eckert L et al (2022) Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. The Lancet, published online August 8, 2022. 10.1016/S1473-3099(22)00291-2
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Hamrén UW, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T, MELODY study group (2022) Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 386(9):837–846. 10.1056/nejmoa2110275 DOI: 10.1056/nejmoa2110275
Raes M, Cox B, Strens D (2018) Seasonality of respiratory syncytial virus (RSV) in Belgium. Belgian J Paediatrics 216
Williams TC, Sinha I, Barr IG, Zambon M (2021) Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic. Eurosurveillance 26(29):2100186. 10.2807/1560-7917.es.2021.26.29.2100186 DOI: 10.2807/1560-7917.es.2021.26.29.2100186
Foley DA, Phuong LK, Peplinski J, Lim SM, Lee WH, Farhat A, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, Le H, Levy A, Hoeppner T, Borland ML, Hazelton B, Moore HC, Blyth C, Yeoh DK, Bowen AC (2022) Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. Arch Dis Child 107:322507. 10.1136/archdischild-2021-322507 DOI: 10.1136/archdischild-2021-322507
Sciensano (2022) Health topics influenza. Retrieved from https://www.sciensano.be/en/health-topics/influenza/role-0. Accessed 20 Apr 2022
Subissi L, Bossuyt N, Reynders M, Gérard M, Dauby N, Lacor P, Daelemans S, Lissoir B, Holemans X, Magerman K, Jouck D, Bourgois M, Delaere B, Quolin S, Van Gucht S, Thomas I, Barbezange C (2021) Spotlight influenza: extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019. Eurosurveillance 26(38):2001104. 10.2807/1560-7917.es.2021.26.38.2001104 DOI: 10.2807/1560-7917.es.2021.26.38.2001104
Vega T, Lozano JE, Meerhoff T, Snacken R, Mott J, Ortiz de Lejarazu R, Nunes B (2013) Jul) Influenza surveillance in Europe: establishing epidemic thresholds by the moving epidemic method. Influen Other Respir Vir 7(4):546–558. 10.1111/j.1750-2659.2012.00422.x DOI: 10.1111/j.1750-2659.2012.00422.x
